Vofatamab
As of the edition of 20 October 2026, Vofatamab is an antibody: stopped in 2019; acts on FGFR3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2019
- Kind
- Antibody
- Registered trials
- 6, 4 stopped early
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Digestive system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Vofatamab.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FGFR3 | Fibroblast growth factor receptor 3 | P22607 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 3 | 0 | 0 | 3 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Roche | Lead sponsor of trials | 2010 to now |
| Rainier Therapeutics | Lead sponsor of trials | 2015 to now |
| Fusion Pharmaceuticals | Lead sponsor of trials | 2022 to now |